Calcium Carbonate-Based Mucoadhesive Microcontainers for Intranasal Delivery of Drugs Bypassing the Blood–Brain Barrier

被引：27

作者：

Borodina T.N. ^{[1
]}

Trushina D.B. ^{[1
,2
,3
]}

Marchenko I.V. ^{[1
,3
]}

Bukreeva T.V. ^{[1
,3
]}

机构：

[1] Shubnikov Institute of Crystallography of Federal Scientific Research Centre “Crystallography and Photonics” of Russian Academy of Sciences, Leninskii pr. 59, Moscow

[2] Faculty of Physics, Lomonosov Moscow State University, Leninskie Gory 1, b.2, Moscow

[3] National Research Centre “Kurchatov Institute”, pl. Akademika Kurchatova 1, Moscow

来源：

Trushina, D.B. (trushina.d@mail.ru) | 2016年 / Springer Science and Business Media, LLC卷 / 06期

基金：

俄罗斯基础研究基金会;

关键词：

Anesthetic; Avoidance of blood–brain barrier; Calcium carbonate microparticles; Drug delivery; Intranasal administration; Microcontainers; Mucoadhesive polymer;

D O I：

10.1007/s12668-016-0212-2

中图分类号：

学科分类号：

摘要：

There is an opinion in the medical associations that intranasal administration of medicine allows direct olfactory transfer of drugs into the central nervous system bypassing the blood–brain barrier. This approach could be a valuable solution to the problem of cerebral pathology treatment. We propose a new system of microcontainers for the delivery of an active component to the brain by intranasal administration. The microcontainers were fabricated on the base of porous calcium carbonate particles modified with mucoadhesive biocompatible polymer or polymer/surfactant coating. Loperamide was encapsulated in the proposed microcontainers as a model drug, which cannot pass the blood–brain barrier. The efficiency of microcontainers loaded with the anesthetic loperamide has been assessed by the formalin test in rats in vivo. The results of the in vivo experiments demonstrate decrease in the pain sensitivity after intranasal administration of proposed system, and benefit of mucoadhesive biocompatible coating aiming to improve the anesthetic effect. © 2016, Springer Science+Business Media New York.

引用

页码：261 / 268

页数：7

共 39 条

[1] Pathak Y.V., Handbook of nutraceuticals volume I: ingredients, formulations, and applications, Handbook of nutraceuticals volume I: ingredients, formulations, and applications, pp. 292-306, (2009)
[2] Graham N., Steiner T.J., Kesserling J., Neurological disorders: Public health challenges (p. 28–37). Geneva, Switzerland, (2007)
[3] Pond S.M., Tozer T.N., First-pass elimination. Basic concepts and clinical consequences, Clinical Pharmacokinetics, 9, 1, pp. 1-25, (1984)
[4] Sakane T., Akizuki M., Yoshida M., Yamashita S., Nadai T., Hashida M., Et al., Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity, Journal of Pharmacy and Pharmacology, 43, 6, pp. 449-451, (1991)
[5] Banks W.A., During M.J., Niehoff M.L., Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration, Journal of Pharmacology and Experimental Therapeutics, 309, 2, pp. 469-475, (2004)
[6] Westin U.E., Bostrom E., Grasjo J., Hammarlund-Udenaes M., Bjork E., Direct nose-to-brain transfer of morphine after nasal administration to rats, Pharmaceutical Research, 23, 3, pp. 565-572, (2006)
[7] Jadhav K., Gambhire M., Shaikh I., Kadam V., Pisal S., Nasal drug delivery system-factors affecting and applications, Current Drug Theraphy, 2, 1, pp. 27-38, (2007)
[8] Mathison S., Nagilla R., Kompella U.B., Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?, Journal of Drug Targeting, 5, 6, pp. 415-441, (1998)
[9] Illum L., Is nose-to-brain transport of drugs in man a reality?, Journal of Pharmacy and Pharmacology, 56, 1, pp. 3-17, (2004)
[10] Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., Et al., Effective nasal influenza vaccine delivery using chitosan, Vaccine, 23, 35, pp. 4367-4374, (2005)

← 1 2 3 4 →